|Title:||Bone Health in Sarcoidosis|
|Author(s):||L Kingsmore T Scullion E Murtagh J Burns P Minnis|
|Institution:||Antrim Area Hospital|
|Poster:||Click to view poster|
|Abstract:||The mainstay treatment of sarcoidosis is corticosteroid therapy, which often|
complicates bone health. We examined all patients attending the ILD clinic with
sarcoidosis within 1 year for radiological involvement and axial bone health.
Baseline data was collated from 184 patients. 9 patients (5%) had reported
evidence of appendicular involvement on imaging. 14% were treated with
hydroxychloroquine. Treatment naïve patients tended to osteopenia BMD 0.952 g/cm 2 (T s -1.27), in comparison to treated patients lumbar BMD 1.061 g/cm 2 (T s -0.8). BMD were similar between those treated with low dose prednisolone and combination agents. Stratification by CXR stage indicated similarities between stage 0 and 4 in terms of treatment rates 89% versus 79% and BMD 1.021 g/cm 2 (T s -0.73) versus 1.06g/cm 2 (T s -0.77). Inflammatory CXR stages 1-3 had a lower treatment rate (53%) and lower BMD 1.00 g/cm 2 (T score -1.19). The majority of patients were sufficient in Vitamin D (64%) at time of testing.
There appears to be mechanisms outside corticosteroid induced net bone loss
at play in patients with sarcoidosis. This data suggests a link between bone health and active pulmonary sarcoidosis that could not be explained by treatment or vitamin D deficiency.